NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations

Pharmacogenetics

Volumn 8, Issue 4, 1998, Pages 305-313

  Gaedigk, Andrea ^a   Tyndale, Rachel F ^b   Jurima Romet, Malle ^c   Sellers, Edward M ^d   Grant, Denis M ^e   Leeder, J Steven ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Bureau of Drug Research   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Allele frequency; Ethnicity; NQO1; Polymorphism

Indexed keywords

MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CANADA; CARCINOGENICITY; CAUCASIAN; CHINESE; DRUG METABOLISM; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIAN; MUTAGENICITY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CANADA; CHINA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; INDIANS, NORTH AMERICAN; MOLECULAR SEQUENCE DATA; NAD(P)H DEHYDROGENASE (QUINONE); PHENOTYPE; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; TERMINOLOGY;

STAPHYLOCOCCUS PHAGE 187;

EID: 0031826289     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199808000-00004     Document Type: Article

References (43)

1. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D, Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones; quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995; 48:499-504.
2. Beal HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D. Role of NAD(P)H;quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996; 51:645-652.
3. Belinsky M, Jaiswal AK. NAD(P)H;quinone oxidoreductase 1 (DT-diaphorase expression in normal and tumor tissues. Cancer Metastasis Rev 1993; 12:103-117.
4. Broly F, Gaedigk A, Heim U, Eichelbaum M, Mörike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in European populations. DNA Cell Biol 1991; 10:545-557.
5. Dahl ML, Yue Q-Y, Roh HK, Johansson I, Sawe J, Sjoqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5:159-164.
6. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
7. Edwards YH, Potter J, Hopkinson DA. Human FAD-dependent NAD(P)H diaphorase. Biochem J 1980; 187:429-436.
8. Eickelmann P, Schulz WA, Rohde D, Schmitz-Dräger B, Sies H. Loss of heterozygosity at the NAD(P)H;quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 1994; 375:439-445.
9. Gibson NW, Hartley JA, Butler J, Siegel D, Ross D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 1992; 42:531-536.
10. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental. Caucasian. Saudi Arabian and American black populations. Pharmacogenetics 1997; 7:59-64.
11. Grant DM, Hughes NC, Janezie SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mut Res 1997; 376:61-70.
12. Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA. Impression of human NAD(P)H;quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells; effect on the toxicity of antitumor quinones. Mol Pharmacol 1996; 50:728-735.
13. Hayes RB, Dosemeci M, Li GL, Wacholder S, Chow WH, Rothman N, et al. Mortality among benzene-exposed workers in China. Environ Health Perspect 1996; 104:1349-1352.
14. Jaiswal AK, Human NAD(P)H;quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991; 30:10647-10653.
15. Joseph P, Xie T, Xu Y, Jaiswal AK. NAD(P)H;quinone reductase 1 (DT)diaphorase; expression, regulation, and role in cancer. Oncol Res 1994; 6:525-532.
16. Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 1996; 6:329-339.
17. Jurima-Romet M, Foster BC, Rode A, Casley WL, Vloshinsky P, Huang HS, et al. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can J Physiol Pharmacol 1997; 75:165-172.
18. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo Z-F, Spitz MR, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997; 76:852-854.
19. Kuehl BL, Paterson JWE, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995; 72:555-561.
20. Lind C, Hochstein P, Ernster L. DT-diaphorase as a quinone reductase; a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 1982; 216:178-185.
21. Linet MS, Yin SN, Travis LB, Li CY, Zhang ZN, Rothman N. et al. Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. Environ Health Perspect 1996; 104:1353-1364.
22. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-296.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16:1215.
24. Nowak MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a Canadian Native Indian Population. Pharmacogenetics 1997; 7:145-148.
25. Pan S-S, Forrest GL, Akman SA, Hu LT. NAD(P)H;quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res 1995; 55:330-335.
26. Prakash AS, Beall H, Ross D, Gibson NW. Sequence-selective alkylation and cross-linking induced by mitomycin C upon activation by DT-diaphorase. Biochemistry 1993; 32:5518-5525.
27. Rosner B. The Chi-square goodness-of-fit test. In: editors. Fundamentals in biostatistics. New York: Duxbury Press; 1990. pp. 376-381.
28. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol 1996; 60(suppl):111-118.
29. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 1994; 6:493-500.
30. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H;quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 1996; 74:995-996.
31. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H;quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995; 5:199-206.
32. Rothman N, Li GL, Dosemeci M, Bechtold WE, Marti GE, Wang YZ, et al. Hematotoxity among Chinese workers heavily exposed to benzene. Am J Ind Med 1996; 29:236-246.
33. Rothman N, Smith MT, Hayes RB, Traver RD. Hoener B-A, Campleman S, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1609C-T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997; 57:2839-2842.
34. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H;quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7:235-239.
35. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of diaziquone by NAD(P)H;(quinone acceptor)oxidoreductase (DT-diaphorase); role in diaziquone-induced DNA damage and cytotoxicity in human carcinoma cells. Cancer Res 1990; 50:7293-7300.
36. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of α-tocopherolquinone by human NAD(P)H;quinone oxidoreductase: the role of α-tocopherolhydroquinone as a cellular antioxidant. J Pharmacol Exp Ther 1997; 52:300-305.
37. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P4502C9 locus. Pharmacogenetics 1996; 6:429-439.
38. Torroni A, Schurr TG, Cabell MF, Brown MD, Neel JV, Larsen M, et al. Asian affinities and continental radiation of the four founding Native American mtDNAs. Am J Hum Genet 1993; 53:563-590.
39. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, et al. NAD(P)H;quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52:797-802.
40. Traver RD, Siegel D, Beall HD, Phillips RM, Franklin WA, Ross D. Characterization of a polymorphism in NAD(P)H;quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997; 75:69-75.
41. Vatsis KP, Weber VVW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-17.
42. Winner EJ, Prough RA, Brennan MD. Human NAD(P)H;quinone oxidoreductase induction in human hepatoma cells after exposure to industrial acylates, phenolics, and metals. Drug Metab Dispos 1997; 25:175-181.
43. Yao KS, Hageboutros A, Ford P, O'Dwyer PJ. Involvement of activator protein-1 and nuclear factor-kappaB transcrition factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol Pharmacol 1997; 51:422-430.